Jefferies analyst Maury Raycroft highlights Karyopharm Therapeutics (KPTI) and Reata Pharmaceuticals (RETA) as two stocks to focus on in 2019. Karyopharm has important regulatory updates upcoming with an expected FDA panel for selinexor in penta-refractory multiple myeloma and then an FDA action date scheduled for April 6, Raycroft tells investors in a research note. And Reata is expected to report initial, awaited focal segmental glomerulosclerosis data in the first half of 2019 and then two pivotal readouts in the second half in Alport syndrome and Friedreich's ataxia, adds the analyst. He believes the current share weakness offers an "appealing entry point" for Karyopharm.